title: Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas.
abstract: Dramatic progress in the understanding of underlying disease biology and the development of novel therapeutics has yielded a revolution that is poised to transform the face of lymphoma treatment across a broad spectrum of histologies. Ongoing randomized clinical trials are poised to unseat long-entrenched standards of care in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and Hodgkin lymphoma. Emerging treatment approaches are reviewed, including optimization of existing chemoimmunotherapy platforms, development of chemotherapy-sparing immunotherapy for follicular lymphoma, biologically targeted therapy for subsets of diffuse large B-cell lymphoma, and incorporation of novel agents into the treatment of mantle cell lymphoma and peripheral T-cell lymphoma. Novel therapies in early stage trials with future promise of redefining standards of care are also reviewed for non-Hodgkin and Hodgkin lymphomas, including small molecule pathway inhibitors and advances in immunotherapy.
authors: Center for Lymphoma, Massachusetts General Hospital Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA. Electronic address: jabramson@mgh.harvard.edu.
authors: Jeremy S
authors: JS
authors: Abramson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*
keywords: Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Novel Agents; Peripheral T-cell Lymphoma